Methotrexate as a corticosteroid-sparing agent in leprosy reactions: A French multicenter retrospective study
PLOS Neglected Tropical Diseases · 2023
DOI: 10.1371/journal.pntd.0011238 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift PLOS Neglected Tropical Diseases, 2023. Verfasst von Léa Jaume und 15 weiteren Autor:innen. Beteiligte Einrichtung: Dermatologie et vénérologie, Hôpital Saint-Louis, Université Paris Cité, Paris, France. Hauptthemen laut MEDLINE: Erythema Nodosum, Leprosy, Leprosy, Lepromatous. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Leprosy reactions (LRs) are inflammatory responses observed in 30%-50% of people with leprosy. First-line treatment is glucocorticoids (GCs), often administered at high doses with prolonged courses, resulting in high morbi-mortality. Methotrexate (MTX) is an immunomodulating agent used to treat inflammatory diseases and has an excellent safety profile and worldwide availability. In this study, we describe the efficacy, GCs-sparing effect and safety of MTX in LRs.
Methods
We conducted a retrospective multicentric study in France consisting of leprosy patients receiving MTX for a reversal reaction (RR) and/or erythema nodosum leprosum (ENL) since 2016. The primary endpoint was the rate of good response (GR) defined as the complete disappearance of inflammatory cutaneous or neurological symptoms without recurrence during MTX treatment. The secondary endpoint was the GCs-sparing effect, safety and clinical relapse after MTX discontinuation.
Results
Our study included 13 patients with LRs (8 men, 5 women): 6 had ENL and 7 had RR. All patients had had at least one previous course of GCs and 2 previous treatment lines before starting MTX. Overall, 8/13 (61.5%) patients had GR, allowing for GCs-sparing and even GCs withdrawal in 6/11 (54.5%). No severe adverse effects were observed. Relapse after MTX discontinuation was substantial (42%): the median relapse time was 5.5 months (range 3–14) after stopping treatment.
Conclusion
MTX seems to be an effective alternative treatment in LRs, allowing for GCs-sparing with a good safety profile. Furthermore, early introduction during LRs may lead to a better therapeutic response. However, its efficacy seems to suggest prolonged therapy to prevent recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dermatologie et vénérologie, Hôpital Saint-Louis, Université Paris Cité, Paris, France.
- Maladies infectieuses et tropicales, Hôpital Pitié-Salpêtrière, Paris, France.
- Dermatologie et vénérologie, CH Colmar, Colmar, France.
- Dermatologie et vénérologie, CHU de la Réunion, Saint-Pierre, France.
- INSERM Human Immunology, Physiopathology and Immunotherapy U976, Hospital Saint-Louis, Paris, France.
- Médecine interne, CH Saint Nazaire, Saint-Nazaire, France.
ORCID-Profile: Léa Jaume
Zitieren
APA
Jaume, L., Hau, E., Monsel, G., Mahé, A., Bertolotti, A., Petit, A., Le, B., Chauveau, M., Duhamel, E., Maisonobe, T., Bagot, M., Bouaziz, J. D., Mougari, F., Cambau, E., Jachiet, M., & Groupe d’infectiologie en dermatologie et des infections sexuellement transmissibles (GrIDIST) (2023). Methotrexate as a corticosteroid-sparing agent in leprosy reactions: A French multicenter retrospective study. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0011238
Vancouver
Jaume L, Hau E, Monsel G, Mahé A, Bertolotti A, Petit A, et al. Methotrexate as a corticosteroid-sparing agent in leprosy reactions: A French multicenter retrospective study. PLOS Neglected Tropical Diseases. 2023. doi:10.1371/journal.pntd.0011238
BibTeX
@article{Jaume2023,
author = {Jaume, Léa and Hau, Estelle and Monsel, Gentiane and Mahé, Antoine and Bertolotti, Antoine and Petit, Antoine and Le, Britney and Chauveau, Marie and Duhamel, Elisabeth and Maisonobe, Thierry and Bagot, Martine and Bouaziz, Jean-David and Mougari, Faïza and Cambau, Emmanuelle and Jachiet, Marie and Groupe d’infectiologie en dermatologie et des infections sexuellement transmissibles (GrIDIST), Groupe d’infectiologie en dermatologie et des infections sexuellement transmissibles (GrIDIST)},
title = {Methotrexate as a corticosteroid-sparing agent in leprosy reactions: A French multicenter retrospective study},
journal = {PLOS Neglected Tropical Diseases},
year = {2023},
doi = {10.1371/journal.pntd.0011238}
}
EUVIMED